Bayer Stands at a Legal and Financial Precipice as Two High-Stakes Deadlines Converge

Bayer's shares rise 2.6% as US Supreme Court nears Durnell ruling; €32.5B debt and €5B legal costs weigh on pipeline-driven strategy.

The clock is ticking in Washington. In the coming days, the US Supreme Court is expected to rule on the “Durnell” case, a decision that could fundamentally alter Bayer’s legal landscape. The market is holding its breath: the shares changed hands at €38.89 on Wednesday, up 2.6% on the day, but the real catalyst is still to come.

That share-price move came as Bayer finalised the acquisition of Perfuse Therapeutics, a privately held biotech specialising in ophthalmology. The deal gives Bayer exclusive rights to PER-001, a phase-II investigational implant for retinal disease. The upfront payment is $300m, and milestone payments could push the total to $2.45bn. It is a classic “pipeline insurance” move – a bet on a high-risk, high-reward asset – but it also feeds into a growing tension inside the company.

The Cash-Flow Squeeze

Bayer’s financial position remains precarious despite operational progress. Net debt swelled to more than €32.5bn at the end of March 2026, eroding nearly all of the roughly €3bn reduction achieved last year. Free cash flow swung to minus €2.3bn in the first quarter, driven largely by around €2bn in net legal outlays. The question is whether the pharma pipeline can generate enough cash to cover ongoing litigation, new acquisitions and debt reduction all at once.

That is the essence of the two-track strategy the management is trying to execute. On one hand, the operational business is gaining momentum. Currency-adjusted sales rose 4% in the first quarter to €13.4bn, and adjusted earnings per share came in at €2.71. Key drugs such as Nubeqa and Kerendia are driving growth, and the expanded FDA approval for Kerendia last year has reinforced the portfolio. Positive phase-III data for the stroke drug Asundexian add to the optimism. On the company’s Pharma Media Day, management reiterated its goal of achieving a roughly 30% operating margin in the pharma division by 2030.

On the other hand, the legal burden is not easing. Bayer expects legal costs of around €5bn in 2026 for glyphosate and PCB cases. The acquisition of Perfuse Therapeutics adds immediate cash outflows with returns that are years away. This dynamic has kept the stock from fully recovering its lost ground: the shares are up about 43% from their 52-week low of €25.09, but they remain more than 24% below the year’s high near €50.

The Supreme Court’s Role

This week’s Supreme Court ruling in the Durnell case is the first of two critical legal events. Analysts at UBS put the odds of a favourable outcome for Bayer at 70%. If the ruling goes the company’s way, structural legal uncertainty would drop significantly. The second event comes in July, when a final hearing is scheduled on the proposed class settlement for glyphosate cases. If that settlement collapses, the debt load could escalate again. If it holds, Bayer could release substantial provisions, accelerating the deleveraging process.

The stock’s technical picture offers some comfort but no guarantees. The current price of €38.89 is roughly 3% above the 50-day moving average and about 7% above the 200-day average at €36.33. A solid base at that longer-term trendline has provided support. The next resistance is the 100-day line near €39.58. Analysts’ price targets are all over the map, ranging from below €35 to above €55, with UBS flagging a worst-case scenario as low as €28.

Two Tracks, One Outcome

Investors are weighing two starkly different futures. In the bullish case, the pharma pipeline delivers sustained growth, the Supreme Court ruling favours Bayer, and the glyphosate settlement sticks. That would free up cash, drive down debt, and allow the stock to break decisively above €40. In the bearish case, the legal drain continues, the Perfuse acquisition becomes a burden, and the debt mountain grows. A break below the €36.33 support could trigger a sharp sell-off.

The next two months will be decisive. The Supreme Court decision is expected as early as this week. Then in August, Bayer will report second-quarter results, and the new chief financial officer’s commentary on cash flow will be parsed for every nuance. For now, the shares are caught between a promising pipeline and a punishing legal calendar – a balancing act that will determine whether the 43% gain since the low is the start of a sustained recovery or just a temporary reprieve.